UK NEQAS for H&I Schemes & Rationale

SCHEME 1A – HLA PHENOTYPING
To assess participants’ ability to use serological and supplementary methods to correctly identify HLA specificities.

SCHEME 1B – HLA-B27 TESTING
To assess participants’ ability to correctly determine the HLA-B27/B2708/B*27 status as positive or negative.

SCHEME 2A – CYTOTOXIC CROSSMATCHING
To assess participants’ ability to correctly determine cell/serum cytotoxic crossmatch status.

SCHEME 2B – CROSSMATCHING BY FLOW CYTOMETRY
To assess participants’ ability to correctly determine cell/serum flow cytometry crossmatch status.

SCHEME 3 – HLA ANTIBODY SPECIFICITY ANALYSIS
To assess the laboratory’s ability to determine the component HLA specificity or specificities in the antisera using all methods the laboratory employs for clinical samples.

SCHEME 4A1 – DNA HLA TYPING AT 1ST FIELD RESOLUTION
To assess participants’ ability to correctly determine HLA alleles at the 1st field level.

SCHEME 4A2 – DNA HLA TYPING TO 2ND OR 3RD FIELD RESOLUTION
To assess participants’ ability to correctly determine HLA alleles to the 2nd or 3rd field level.

SCHEME 5A – HFE TYPING
To assess participants’ ability to correctly determine HFE mutations.

SCHEME 5B – INTERPRETATIVE: HFE GENOTYPE AND HEREDITARY HAEMOCHROMATOSIS
To assess participants’ ability to make an accurate, clear and concise clinical report, appropriate for the range of clinical staff involved in a patient’s care and treatment, given HFE genotype and other relevant clinical information.

SCHEME 6 – HLA ANTIBODY DETECTION
To assess participants’ ability to correctly determine the presence of HLA antibodies using all ‘screening’ methods the laboratory employs for clinical samples.

SCHEME 7 – HLA-B*57:01 TYPING FOR DRUG HYPERSENSITIVITY
To assess participants’ ability to correctly determine HLA-B*57:01 status.

SCHEME 8 – HLA GENOTYPING FOR COELIAC AND OTHER HLA ASSOCIATED DISEASES
To assess participants’ ability to correctly determine disease associated HLA allele families/alleles.

SCHEME 9 – KIR GENOTYPING
To assess participants’ ability to correctly determine the presence or absence of specific KIR genes.

SCHEME 10 – HPA GENOTYPING
To assess participants’ ability to correctly determine HPA polymorphisms.

SCHEME 11 – HPA ANTIBODY DETECTION/SPECIFICATION
To assess participants’ ability to correctly detect the presence of and determine the specificity of HPA antibodies.

EDUCATIONAL SCHEME and INTERPRETIVE EDUCATION SCHEME
To provide participants with a variety of interesting samples/scenarios to test that offer a beneficial educational element.